A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Phase of Trial: Phase III
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Efpeglenatide (Primary) ; Metformin; Sulfonylureas
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms AMPLITUDE-S
- Sponsors Sanofi
- 24 Sep 2019 Planned End Date changed from 1 Jun 2021 to 1 Oct 2021.
- 24 Sep 2019 Planned primary completion date changed from 1 Jun 2021 to 1 Oct 2021.
- 21 Aug 2019 Planned primary completion date changed from 1 Feb 2021 to 1 Jun 2021.